Cardiovascular-Related Mortality Risk in Primary Myelofibrosis in Pre-Ruxolitinib and Ruxolitinib Eras

被引：0
|
作者：
Ilerhunmwuwa, Nosakhare Paul [1 ]
Rayapureddy, Aditya Keerthi [2 ]
Uche, Ifeanyi Nnamdi [1 ]
Wasifuddin, Mustafa [3 ]
Wang, Jen-Chin [4 ]
机构：
[1] Brookdale Univ Hosp & Med Ctr, Dept Med, Brooklyn, NY USA
[2] Interfaith Med Ctr, Dept Med, Brooklyn, NY USA
[3] Brookdale Univ Hosp & Med Ctr, Brooklyn, NY USA
[4] Brookdale Univ Hosp & Med Ctr, Div Hematol Oncol, Brooklyn, NY USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174418
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib
    Benoit Branco
    David Metsu
    Marine Dutertre
    Bruno Marchou
    Pierre Delobel
    Christian Recher
    Guillaume Martin-Blondel
    Annals of Hematology, 2016, 95 : 1207 - 1209
  • [32] TREATMENT WITH RUXOLITINIB IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS: SINGLE CENTER EXPERIENCE
    Sotiropoulos, D.
    Papaioannou, G.
    Iskas, M.
    Karavalakis, G.
    Bousiou, Z.
    Athanasiadou, A.
    Gaitatzi, M.
    Stavroyianni, N.
    Lalayanni, C.
    Touloumenidou, T.
    Kalaitzidou, V.
    Anagnostopoulos, A.
    HAEMATOLOGICA, 2015, 100 : 759 - 760
  • [33] Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient With Primary Myelofibrosis on Ruxolitinib
    Kumar, Sandhya Shanthosh
    Nagesh, Vignesh Krishnan
    Sivakolundu, Keerthana P.
    Ali, Bahadur
    Sange, Ibrahim
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [34] Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
    Arun Rajasekaran
    Thuy-Trang Ngo
    Maen Abdelrahim
    William Glass
    Amber Podoll
    Srdan Verstovsek
    Ala Abudayyeh
    BMC Nephrology, 16
  • [35] Local experience with ruxolitinib in primary and secondary myelofibrosis: an analysis of 10 patients treated with ruxolitinib in the Hull and East Yorkshire NHS Trust
    Owen, M. L.
    Ali, S.
    Green, S.
    Fletcher, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 77 - 78
  • [36] Real-life ruxolitinib experience in intermediate-risk myelofibrosis
    Arikan, Fatma
    Toptas, Tayfur
    Atagunduz, Isik Kaygusuz
    Ercan, Tarik
    Oruc, Ozen
    Yilmaz, Fergun
    Tuglular, Tulin
    BLOOD RESEARCH, 2021, 56 (04) : 322 - 331
  • [37] Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia
    Pope, Victor
    Hsia, Cyrus C.
    ANNALS OF HEMATOLOGY, 2024, 103 (02) : 677 - 679
  • [38] Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis: A Phase 2 Study
    Harrison, Claire
    Garcia, Jacqueline S.
    Mesa, Ruben
    Somervaille, Tim
    Ritchie, Ellen K.
    Komrokji, Rami S.
    Pemmaraju, Naveen
    Jamieson, Catriona
    Papadantonakis, Nikolaos
    Foran, James M.
    O'Connell, Casey L.
    Verstovsek, Srdan
    Jung, Paul
    Holes, Leanne
    Masud, Abdullah
    Harb, Jason
    Hutti, Jessica E.
    Prchal, Josef T.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S325 - S325
  • [39] Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia
    Victor Pope
    Cyrus C. Hsia
    Annals of Hematology, 2024, 103 : 677 - 679
  • [40] Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib
    Zhou, Amy
    Kong, Tim
    Fowles, Jared S.
    Jung, Chun-Ling
    Allen, Maggie J.
    Fisher, Daniel A. C.
    Fulbright, Mary
    Nemeth, Elizabeta
    Ganz, Tomas
    Oh, Stephen T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (04) : E49 - E52
12345